Diagnosis and staging of islet cell tumors of the pancreas

Current gastroenterology reports

Volumn 2, Issue 2, 2000, Pages 159-164

  Somogyi, Lehel ^a   Mishra, Girish ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOSTATIN RECEPTOR;

ADENOCARCINOMA; ALGORITHM; ANGIOGRAPHY; CANCER STAGING; ENDOSCOPIC ECHOGRAPHY; GASTRINOMA; HUMAN; INSULINOMA; METASTASIS; METHODOLOGY; PANCREAS ISLET CELL CARCINOMA; PANCREAS TUMOR; PHYSIOLOGY; PROGNOSIS; REVIEW; SCINTISCANNING;

ADENOCARCINOMA; ALGORITHMS; ANGIOGRAPHY; CARCINOMA, ISLET CELL; ENDOSONOGRAPHY; GASTRINOMA; HUMANS; INSULINOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RADIONUCLIDE IMAGING; RECEPTORS, SOMATOSTATIN;

EID: 0034168202     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-000-0100-2     Document Type: Review

References (51)

1. 1. G Cadiot R Lebtahi L Sarda 1996 Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy Gastroenterology 111 845 854 8831579 10.1016/S0016-5085(96)70052-5 1:STN:280:DyaK28vivVCktA%3D%3D Cadiot G, Lebtahi R, Sarda L, et al.: Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Gastroenterology 1996, 111:845–854.
2. 2. HR Alexander DL Fraker JA Norton 1998 Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome Ann Surg 228 228 238 9712569 10.1097/00000658-199808000-00013 1:STN:280:DyaK1czns1Citg%3D%3D Alexander HR, Fraker DL, Norton JA, et al.: Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 1998, 228:228–238.
3. 3. GQ Phan CJ Yeo RH Hruban 1998 Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients J Gastrointest Surg 2 472 482 9843608 10.1016/S1091-255X(98)80039-5 1:STN:280:DyaK1M%2FlvF2qtw%3D%3D Phan GQ, Yeo CJ, Hruban RH, et al.: Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg 1998, 2:472–482.
4. 4. B Eriksson K Oberg B Skogseid 1989 Neuroendocrine pancreatic tumors: clinical findings in a prospective study of 84 patients Acta Oncol 28 373 377 2472825 1:STN:280:DyaL1Mzgt1OlsA%3D%3D Eriksson B, Oberg K, Skogseid B: Neuroendocrine pancreatic tumors: clinical findings in a prospective study of 84 patients. Acta Oncol 1989, 28:373–377.
5. 5. KD Buchanan CF Johnston MM O’Hare 1986 Neuroendocrine tumors: a European view Am J Med 81 suppl 6B 14 22 2879446 10.1016/0002-9343(86)90581-4 1:STN:280:DyaL2s%2FpslehtQ%3D%3D Buchanan KD, Johnston CF, O’Hare MM, et al.: Neuroendocrine tumors: a European view. Am J Med 1986, 81 (suppl 6B):14–22.
6. 6. W Kimura A Kuroda Y Morioka 1990 Clinicopathologic study on minute endocrine tumors of the pancreas: analysis of autopsy cases Nippon Shokakibyo Gakkai Zasshi 87 1191 1202 1974656 1:STN:280:DyaK3czksl2ltw%3D%3D Kimura W, Kuroda A, Morioka Y: Clinicopathologic study on minute endocrine tumors of the pancreas: analysis of autopsy cases. Nippon Shokakibyo Gakkai Zasshi 1990, 87:1191–1202.
7. 7. RT Jensen 1999 Pancreatic endocrine tumors: recent advances Ann Oncol 10 suppl 4 170 176 10436815 10.1023/A:1008350517079 Jensen RT: Pancreatic endocrine tumors: recent advances. Ann Oncol 1999, 10 (suppl 4):170–176.
8. 8. RT Jensen JA Norton 1998 Endocrine tumors of the pancreas MH Sleisenger M Feldman BF Scharschmidt Gastrointestinal and Liver Disease WB Saunders Philadelphia 871 894 Jensen RT, Norton JA: Endocrine tumors of the pancreas. In Gastrointestinal and Liver Disease. Edited by Feldman M, Scharschmidt BF, Sleisenger MH. Philadelphia: WB Saunders; 1998:871–894.
9. 9. CA Maurer C Glaser JC Reubi 1997 Carcinoid of the pancreas Digestion 58 410 4 9324172 1:STN:280:DyaK2svmsVemsw%3D%3D Maurer CA, Glaser C, Reubi JC, et al.: Carcinoid of the pancreas. Digestion. 1997, 58:410–4.
10. 10. C Mao Attar A el DR Domenico 1998 Carcinoid tumors of the pancreas: status report based on two cases and review of the world’s literature Int J Pancreatol 23 153 164 9629513 1:STN:280:DyaK1c3ptlWmug%3D%3D Mao C, el Attar A, Domenico DR, et al.: Carcinoid tumors of the pancreas: status report based on two cases and review of the world’s literature. Int J Pancreatol 1998, 23:153–164.
11. 11. C Mao P Carter P Schaefer 1995 Malignant islet cell tumor associated with hypercalcemia Surgery 117 37 40 7809834 10.1016/S0039-6060(05)80227-2 1:STN:280:DyaK2M7gvVOrtg%3D%3D Mao C, Carter P, Schaefer P, et al.: Malignant islet cell tumor associated with hypercalcemia. Surgery. 1995, 117:37–40.
12. 12. A Fleury JF Flejou A Sauvanet 1998 Calcitonin-secreting tumors of the pancreas: about six cases Pancreas 16 545 50 9598818 10.1097/00006676-199805000-00014 1:STN:280:DyaK1c3lvVOltw%3D%3D Fleury A, Flejou JF, Sauvanet A, et al.: Calcitonin-secreting tumors of the pancreas: about six cases. Pancreas 1998, 16:545–50.
13. 13. H Frucht JL Doppman JA Norton 1989 Gastrinomas: comparison of MR imaging with CT, angiography, and US Radiology 171 713 717 2655004 1:STN:280:DyaL1M3ktFajug%3D%3D Frucht H, Doppman JL, Norton JA, et al.: Gastrinomas: comparison of MR imaging with CT, angiography, and US. Radiology 1989, 171:713–717.
14. 14. AK Galiber CC Reading JW Charboneau 1988 Localization of pancreatic insulinoma: Comparison of pre-and intraoperative US with CT and angiography Radiology 166 405 408 2827232 1:STN:280:DyaL1c%2FpvVWlsQ%3D%3D Galiber AK, Reading CC, Charboneau JW, et al.: Localization of pancreatic insulinoma: Comparison of pre-and intraoperative US with CT and angiography. Radiology 1988, 166:405–408.
15. 15. IM Modlin LH Tang 1997 Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today) Gastroenterology 112 583 590 9024313 10.1053/gast.1997.v112.pm9024313 1:STN:280:DyaK2s7ns1Oktg%3D%3D This excellent review article provides a logical approach to the diagnosis of gut neuroendocrine tumors (NET). A table is provided at the outset that summarizes the tactical strategy for evaluation of a gut NET. The authors also discuss the merits of the different imaging modalities available Modlin IM, Tang LH: Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today). Gastroenterology 1997, 112:583–590. This excellent review article provides a logical approach to the diagnosis of gut neuroendocrine tumors (NET). A table is provided at the outset that summarizes the tactical strategy for evaluation of a gut NET. The authors also discuss the merits of the different imaging modalities available.
16. 16. T Zimmer U Stolzel M Bader 1996 Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas Gut 39 562 8 8944566 1:STN:280:DyaK2s%2FpvF2quw%3D%3D Zimmer T, Stolzel U, Bader M, et al.: Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut 1996, 39:562–8.
17. 17. MP Boukhman JM Karam J Shaver 1999 Localization of insulinomas Arch Surg 134 818 822 10443803 10.1001/archsurg.134.8.818 1:STN:280:DyaK1MzntFCjsQ%3D%3D A 13-year retrospective analysis of all patients with confirmed hyperinsulinemia showed that intraoperative ultrasonography is the most reliable test available (> 90%) for preoperative localization Boukhman MP, Karam JM, Shaver J, et al.:: Localization of insulinomas. Arch Surg 1999, 134:818–822. A 13-year retrospective analysis of all patients with confirmed hyperinsulinemia showed that intraoperative ultrasonography is the most reliable test available (> 90%) for preoperative localization.
18. 18. M Orbuch JL Doppman RT Jensen 1995 Localization of pancreatic endocrine tumors Semin Gastrointest Dis 6 90 101 7788287 1:STN:280:DyaK2MzgvVSgtQ%3D%3D Orbuch M, Doppman JL, Jensen RT: Localization of pancreatic endocrine tumors. Semin Gastrointest Dis 1995, 6:90–101.
19. 19. TC III Winter PC Freeny Nghiem H Vu 1996 Extrapancreatic gastrinoma localization: value of arterial-phase helical CT with water as an oral contrast agent Am J Roentgenol 166 51 52 Winter TC III, Freeny PC, Vu Nghiem H: Extrapancreatic gastrinoma localization: value of arterial-phase helical CT with water as an oral contrast agent. Am J Roentgenol 1996, 166:51–52.
20. 20. B Carlson CD Johnson DH Stephens 1993 MRI of pancreatic islet cell carcinoma J Comput Assist Tomogr 17 735 740 8396599 10.1097/00004728-199309000-00013 1:STN:280:DyaK3szotFWhsw%3D%3D Carlson B, Johnson CD, Stephens DH, et al.: MRI of pancreatic islet cell carcinoma. J Comput Assist Tomogr 1993, 17:735–740.
21. 21. F Gibril JC Reynolds JL Doppman 1996 Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study Ann Intern Med 125 26 34 8644985 1:STN:280:DyaK283ksFSkug%3D%3D Gibril F, Reynolds JC, Doppman JL, et al.: Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study. Ann Intern Med 1996, 125:26–34.
22. 22. EP Krenning DJ Kwekkeboom HY Oei 1994 Somatostatinreceptor scintigraphy in gastroenteropancreatic tumors: an overview of European results Ann N Y Acad Sci 733 416 424 7978890 10.1111/j.1749-6632.1994.tb17291.x 1:CAS:528:DyaK2MXjvFWru7o%3D Krenning EP, Kwekkeboom DJ, Oei HY, et al.: Somatostatinreceptor scintigraphy in gastroenteropancreatic tumors: an overview of European results. Ann N Y Acad Sci 1994, 733:416–424.
23. 23. IM Modlin E Cornelius GP Lawton 1995 Use of an isotopic somatostatin receptor probe to image gut endocrine tumors Arch Surg 130 367 373 7710334 1:STN:280:DyaK2M3isFOhsQ%3D%3D Modlin IM, Cornelius E, Lawton GP: Use of an isotopic somatostatin receptor probe to image gut endocrine tumors. Arch Surg 1995, 130:367–373.
24. 24. W Shi CF Johnston KD Buchanan 1998 Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging QJM 91 295 301 9666953 10.1093/qjmed/91.4.295 1:STN:280:DyaK1czjtFGkug%3D%3D Shi W, Johnston CF, Buchanan KD, et al.: Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. QJM 1998, 91:295–301.
25. 25. R Lebtahi G Cadiot L Sarda 1997 Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors J Nucl Med 38 853 858 9189129 1:STN:280:DyaK2szjt12ltQ%3D%3D Lebtahi R, Cadiot G, Sarda L, et al.: Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997, 38:853–858.
26. 26. M Bader K Koppenhagen 1996 Somatostatin receptor scintigraphy in the diagnosis of neuroendocrine gastroenteropancreatic tumors Recent Results Cancer Res 142 137 162 8893340 1:STN:280:DyaK2s%2FkvVGjtg%3D%3D Bader M, Koppenhagen K: Somatostatin receptor scintigraphy in the diagnosis of neuroendocrine gastroenteropancreatic tumors. Recent Results Cancer Res 1996, 142:137–162.
27. 27. H Scherubl M Bader U Fett 1993 Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors Gastroenterology 105 1705 9 7902821 1:STN:280:DyaK2c%2FnsVymsw%3D%3D Scherubl H, Bader M, Fett U, et al.: Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. Gastroenterology 1993, 105:1705–9.
28. 28. A Frilling M Malago H Martin 1998 Use of somatostatin receptor scintigraphy to image extrahepatic metastases of neuroendocrine tumors Surgery 124 1000 1004 9854575 10.1067/msy.1998.93919 1:STN:280:DyaK1M%2FntFOguw%3D%3D Frilling A, Malago M, Martin H, et al.: Use of somatostatin receptor scintigraphy to image extrahepatic metastases of neuroendocrine tumors. Surgery 1998, 124:1000–1004.
29. 29. B Termanini F Gibril JC Reynolds 1997 Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management Gastroenterology 112 335 347 9024287 10.1053/gast.1997.v112.pm9024287 1:STN:280:DyaK2s7ns1Onug%3D%3D Does SRS alter the clinical management in Zollinger-Ellison syndrome? This study emphatically suggests that the clinical management was altered in approximately 50% of patients. Somatostatin receptor scintigraphy aided in primary tumor localization and clarification of equivocal localization results from conventional studies Termanini B, Gibril F, Reynolds JC, et al.: Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997, 112:335–347. Does SRS alter the clinical management in Zollinger-Ellison syndrome? This study emphatically suggests that the clinical management was altered in approximately 50% of patients. Somatostatin receptor scintigraphy aided in primary tumor localization and clarification of equivocal localization results from conventional studies.
30. 30. G Cadiot G Bonnaud R Lebtahi 1997 Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome Gut 41 107 114 9274481 1:STN:280:DyaK2svhvF2ktw%3D%3D 10.1136/gut.41.1.107 Patients with Zollinger-Ellison syndrome and known extra-abdominal metastases were categorized as either sporadic, MEN 1 or liver metastases. SRS detected many abnormalities that modified management in patients with Zollinger-Ellison syndrome, especially those with sporadic disease. Extra-hepatic detection of metastases was highest Cadiot G, Bonnaud G, Lebtahi R, et al.: Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. Gut 1997, 41:107–114. Patients with Zollinger-Ellison syndrome and known extra-abdominal metastases were categorized as either sporadic, MEN 1 or liver metastases. SRS detected many abnormalities that modified management in patients with Zollinger-Ellison syndrome, especially those with sporadic disease. Extra-hepatic detection of metastases was highest.
31. 31. RT Jensen F Gibril B Termanini 1997 Definition of the role of somatostatin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization Yale J Biol Med 70 481 500 9825476 1:CAS:528:DyaK1cXnvVCrs7o%3D Jensen RT, Gibril F, Termanini B: Definition of the role of somatostatin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization. Yale J Biol Med 1997, 70:481–500.
32. 32. F Gibril RT Jensen 1997 Comparative analysis of diagnostic techniques for localization of gastrointestinal neuroendocrine tumors Yale J Biol Med 70 509 522 9825478 1:CAS:528:DyaK1cXnvVCrs7g%3D Gibril F, Jensen RT: Comparative analysis of diagnostic techniques for localization of gastrointestinal neuroendocrine tumors. Yale J Biol Med 1997, 70:509–522.
33. 33. I Virgolini I Szilvasi A Kurtaran 1998 Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients J Nucl Med 39 1928 1936 9829585 1:CAS:528:DyaK1cXnsFWjsbw%3D Virgolini I, Szilvasi I, Kurtaran A, et al.: Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med 1998, 39:1928–1936.
34. 34. T Rösch CJ Lightdale JF Botet 1992 Localization of pancreatic endocrine tumors by endoscopic ultrasonography N Engl J Med 326 1721 1726 1317506 10.1056/NEJM199206253262601 Rösch T, Lightdale CJ, Botet JF, et al.: Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992, 326:1721–1726.
35. 35. JR Glover PJ Shorvon WE Lees 1992 Endoscopic ultrasound for localization of islet cell tumors Gut 33 108 110 1310948 1:STN:280:DyaK387lsFGitw%3D%3D Glover JR, Shorvon PJ, Lees WE: Endoscopic ultrasound for localization of islet cell tumors. Gut 1992, 33:108–110.
36. 36. CJ Lightdale JF Botet JM Woodruff 1991 Localization of endocrine tumors of the pancreas with endoscopic ultrasound Cancer 68 1815 1820 1913525 10.1002/1097-0142(19911015)68:8<1815::AID-CNCR2820680828>3.0.CO;2-B 1:STN:280:DyaK38%2FgsFaksA%3D%3D Lightdale CJ, Botet JF, Woodruff JM, et al.: Localization of endocrine tumors of the pancreas with endoscopic ultrasound. Cancer 1991, 68:1815–1820.
37. 37. L Palazzo G Roseau M Salmeron 1992 Endoscopic ultrasonography in the preoperative localization of pancreatic endocrine tumors Endoscopy 24 350 353 1353019 10.1055/s-2007-1010498 Palazzo L, Roseau G, Salmeron M: Endoscopic ultrasonography in the preoperative localization of pancreatic endocrine tumors. Endoscopy 1992, 24:350–353.
38. 38. C Proye P Malvaux F Pattou 1998 Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy Surgery 124 1134 1143 9854595 10.1067/msy.1998.93109 1:STN:280:DyaK1M%2FntFOmuw%3D%3D Overall sensitivity of combined EUS and SRS was 89% for insulinomas and 93% for gastrinomas, according to this reported study. This study suggests that EUS and SRS for gastrinomas and insulinoma should be the initial preoperative imaging procedures Proye C, Malvaux P, Pattou F, et al.: Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy. Surgery 1998, 124:1134–1143. Overall sensitivity of combined EUS and SRS was 89% for insulinomas and 93% for gastrinomas, according to this reported study. This study suggests that EUS and SRS for gastrinomas and insulinoma should be the initial preoperative imaging procedures.
39. 39. MA Jednak S Carpenter NW Thompson 1999 Endoscopic ultrasound in the diagnosis and management of neuroendocrine tumors of the pancreas Gastroenterology 116 A1161 A1161 Jednak MA, Carpenter S, Thompson NW, et al.: Endoscopic ultrasound in the diagnosis and management of neuroendocrine tumors of the pancreas. Gastroenterology 1999, 116:A1161.
40. 40. JC Huai W Zhang HO Niu 1998 Localization and surgical treatment of pancreatic insulinomas guided by intraoperative ultrasound Am J Surg 175 18 21 9445232 10.1016/S0002-9610(97)00235-3 1:STN:280:DyaK1c7gs1Sisg%3D%3D Huai JC, Zhang W, Niu HO, et al.: Localization and surgical treatment of pancreatic insulinomas guided by intraoperative ultrasound. Am J Surg 1998, 175:18–21.
41. 41. LA Hashimoto RM Walsh 1999 Preoperative localization of insulinomas is not necessary J Am Coll Surg 189 368 373 10509462 10.1016/S1072-7515(99)00163-5 1:STN:280:DyaK1MvjslWlsw%3D%3D Hashimoto LA, Walsh RM: Preoperative localization of insulinomas is not necessary. J Am Coll Surg 1999, 189:368–373.
42. 42. CK Brown DL Bartlett JL Doppman 1997 Intraarterial calcium stimulation and intraoperative ultrasonography in the localization and resection of insulinomas Surgery 122 1189 1193 9426437 10.1016/S0039-6060(97)90226-9 1:STN:280:DyaK1c%2FoslyitQ%3D%3D Brown CK, Bartlett DL, Doppman JL, et al.: Intraarterial calcium stimulation and intraoperative ultrasonography in the localization and resection of insulinomas. Surgery 1997, 122:1189–1193.
43. 43. R Bansal W Tierney S Carpenter 1999 Cost effectiveness of EUS for preoperative localization of pancreatic endocrine tumors Gastrointest Endosc 49 19 25 9869718 10.1016/S0016-5107(99)70440-2 1:STN:280:DyaK1M%2Fosl2qsQ%3D%3D A case-control study matching patients undergoing preoperative EUS with those who underwent surgical exploration prior to the advent of EUS. Results indicate that the EUS group had reduced charges ($2620 vs $4846 per patient). The reduction in charges was due to a decrease in the number of preoperative admissions for angiography Bansal R, Tierney W, Carpenter S, et al.: Cost effectiveness of EUS for preoperative localization of pancreatic endocrine tumors. Gastrointest Endosc 1999, 49:19–25. A case-control study matching patients undergoing preoperative EUS with those who underwent surgical exploration prior to the advent of EUS. Results indicate that the EUS group had reduced charges ($2620 vs $4846 per patient). The reduction in charges was due to a decrease in the number of preoperative admissions for angiography.
44. 44. PL Pereira AJ Roche GW Maier 1998 Insulinoma and islet cell hyperplasia: value of the calcium intraarterial stimulation test when findings of other preoperative studies are negative Radiology 206 703 709 9494488 1:STN:280:DyaK1c7lsFGqsA%3D%3D Pereira PL, Roche AJ, Maier GW, et al.: Insulinoma and islet cell hyperplasia: value of the calcium intraarterial stimulation test when findings of other preoperative studies are negative. Radiology 1998, 206:703–709.
45. 45. K Oberg 1999 Neuroendocrine gastrointestinal tumors: a condensed overview of diagnosis and treatment Ann Oncol 10 suppl 2 S3 S8 10399026 10.1023/A:1027336026601 Oberg K: Neuroendocrine gastrointestinal tumors: a condensed overview of diagnosis and treatment. Ann Oncol 1999, 10 (suppl 2):S3-S8.
46. 46. B Eriksson J Renstrup H Imam 1997 High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects Ann Oncol 8 1041 1044 9402179 10.1023/A:1008205415035 1:STN:280:DyaK1c%2FmtlOksw%3D%3D Eriksson B, Renstrup J, Imam H, et al.: High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol 1997, 8:1041–1044.
47. 47. P; Migliori M; Gullo L Tomassetti 1998 Slow-release lanreotide treatment in endocrine gastrointestinal tumors Am J Gastroenterol 93 1468 1471 9732927 10.1111/j.1572-0241.1998.465_q.x 1:CAS:528:DyaK1cXmtFSnu7g%3D Tomassetti P; Migliori M; Gullo L: Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol 1998, 93:1468–1471.
48. 48. M Frank KJ Klose M Wied 1999 Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors Am J Gastroenterol 94 1381 1387 10235222 1:CAS:528:DyaK1MXjtlyqs70%3D Frank M, Klose KJ, Wied M, et al.: Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999, 94:1381–1387.
49. 49. Janson E Tiensuu B Eriksson K Oberg 1999 Treatment with high dose [ (111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors: evaluation of therapeutic and toxic effects Acta Oncol 38 373 377 10.1080/028418699431465 Tiensuu Janson E, Eriksson B, Oberg K, et al.: Treatment with high dose [ (111)In-DTPA-D-PHE1]-octreotide in patients with neuroendocrine tumors: evaluation of therapeutic and toxic effects. Acta Oncol 1999, 38:373–377.
50. 50. E James JE McGuigan 1998 Zollinger-Ellison syndrome and other hypersecretory states Scharschmidt BF, Sleisenger MH Feldman M Gastrointestinal and Liver Disease WB Saunders Philadelphia 679 695 James E, McGuigan JE: Zollinger-Ellison syndrome and other hypersecretory states. In Gastrointestinal and Liver Disease. Edited by Feldman M, Scharschmidt BF, Sleisenger MH. Philadelphia: WB Saunders; 1998:679–695.
51. 51. GJ Krejs 1996 Gastrointestinal endocrine tumors Scand J Gastroenterol 220 121 123 1:STN:280:DyaK2s%2FlsVSluw%3D%3D Krejs GJ: Gastrointestinal endocrine tumors. Scand J Gastroenterol 1996, 220:121–123.